News brief­ing: As­traZeneca fol­lows Am­gen down KRAS/SHP2 com­bo path; Val­lon Phar­ma­ceu­ti­cals files for $17 mil­lion IPO 

Rev­o­lu­tion Med­i­cines is adding As­traZeneca to its ros­ter of clin­i­cal col­lab­o­ra­tors, lend­ing its lead drug, RMC-4630, for a study pair­ing it with the phar­ma gi­ant’s KRAS G12C pro­gram.

As­traZeneca will spon­sor and con­duct the study once its now pre­clin­i­cal drug is ready for hu­man stud­ies, an arrange­ment sim­i­lar to the deal Rev­o­lu­tion has with Am­gen on so­tora­sib.

“Drug com­bi­na­tions are like­ly to be crit­i­cal for de­feat­ing in­her­ent drug re­sis­tance mech­a­nisms ex­ploit­ed by RAS-ad­dict­ed can­cers,” CEO Mark Gold­smith said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER